MARKET

GRI

GRI

GRI Bio
NASDAQ
2.060
-0.080
-3.74%
After Hours: 2.100 +0.04 +1.94% 19:58 12/05 EST
OPEN
2.030
PREV CLOSE
2.140
HIGH
2.170
LOW
1.990
VOLUME
215.65K
TURNOVER
--
52 WEEK HIGH
16.92
52 WEEK LOW
1.100
MARKET CAP
6.73M
P/E (TTM)
-0.1268
1D
5D
1M
3M
1Y
5Y
1D
GRI Bio Faces Nasdaq Non-Compliance Notice
TipRanks · 4d ago
Gri Bio Faces Nasdaq Delisting Threat Over Equity Rule Violation
Reuters · 4d ago
Weekly Report: what happened at GRI last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at GRI last week (1117-1121)?
Weekly Report · 11/24 09:16
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 11/20 17:05
Promising Interim Results and Strong Financial Position Justify Buy Rating for GRI Bio
TipRanks · 11/19 07:05
Weekly Report: what happened at GRI last week (1110-1114)?
Weekly Report · 11/17 09:15
GRI Bio Q3 EPS $(1.28) Misses $(0.93) Estimate
Benzinga · 11/14 14:28
More
About GRI
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. The Company’s therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The Company is also developing a pipeline of novel type II diverse NKT agonists for the treatment of systemic lupus erythematosus. Its product candidate portfolio also includes GRI-0803 and a proprietary library of more than 500 compounds. It is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) and multiple sclerosis (MS).

Webull offers GRI Bio Inc stock information, including NASDAQ: GRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRI stock methods without spending real money on the virtual paper trading platform.